Funding for this research was provided by:
Stiftung für Rheumaforschung
Received: 2 April 2020
Accepted: 2 October 2020
First Online: 9 October 2020
Ethics approval and consent to participate
: The Ethics committee of the Canton of Zurich (KEK-ZH-Nr. 2014-0439) approved the study. Written informed consent was obtained from all patients prior to inclusion into SCQM.
: Not applicable.
: The SCQM Foundation is supported by the Swiss Society of Rheumatology and by AbbVie, Celgene, Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Samsung, Sandoz, Sanofi, and UCB and has received project-based financial supports from the Arco Foundation, Switzerland, as well as from the Swiss Balgrist Society, Switzerland. AC has received consulting and/or speaking fees from AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly, Merck Sharp & Dohme, Novartis, and Pfizer. MJN has received consulting and/or speaking fees from Abbvie, Eli Lilly, Novartis, and Pfizer. RN, MH, RM, KB, PE, KN, and AS declare that they have no competing interest. No non-financial conflicts of interest exist for any of the authors.